(Q35977609)

11 August 2017

Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy (English)

1 reference

11 August 2017

1 reference

Kevin J Krughoff

2

0 references

author name string

Al B Barqawi

series ordinal

1

1 reference

11 August 2017

Khadijah Eid

series ordinal

3

1 reference

11 August 2017

language of work or name

1 reference

10 May 2012

1 reference

11 August 2017

1 reference

11 August 2017

2012

1 reference

11 August 2017

862639

1 reference

Creative Commons Attribution 3.0 Unported

11 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Image guidance for focal therapy of prostate cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Contemporary outcomes of focal therapy in prostate cancer: what do we know so far…

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

2 October 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Is focal therapy the future for prostate cancer?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Biomarkers for prostate cancer detection

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Screening and prostate-cancer mortality in a randomized European study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Minimally invasive radical prostatectomy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

A concept analysis of uncertainty in illness

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Screening for prostate cancer: estimating the magnitude of overdetection

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Patient preferences for management of localized prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

The role of increasing detection in the rising incidence of prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Progress and problems in screening for carcinoma of the prostate

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Clinical evidence for and implications of the multistep development of prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Serum prostate specific antigen as pre-screening test for prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Comparative effectiveness of minimally invasive vs open radical prostatectomy.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357537

Asymptomatic incidence and duration of prostate cancer

11 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

Re: Trends in radical prostatectomy rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

To tell or not to tell: patterns of disclosure among men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

Treatment decision-making strategies and influences in patients with localized prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

Effective treatment for early-stage prostate cancer--possible, necessary, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

High-intensity focused ultrasound in the management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

Focal therapy meets prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F862639

The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer

21 January 2018

1 reference

12 December 2020

How patients' preferences for risk information influence treatment choice in a case of high risk and high therapeutic uncertainty: asymptomatic localized prostate cancer

1 reference

12 December 2020

Trends in the use of radical prostatectomy for treatment of prostate cancer

1 reference

12 December 2020

Factors Associated With Initial Therapy for Clinically Localized Prostate Cancer: Prostate Cancer Outcomes Study

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study

1 reference

12 December 2020

Latent carcinoma of the prostate

1 reference

12 December 2020

Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies

1 reference

12 December 2020

Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote

1 reference

12 December 2020

Prostate cancer: epidemiology, screening, and biomarkers

1 reference

12 December 2020

Active surveillance: not your father's watchful waiting

1 reference

12 December 2020

The Cautionary Tale of PSA Testing

1 reference

12 December 2020

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

12 December 2020

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

12 December 2020

Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy

1 reference

12 December 2020

Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features

1 reference

12 December 2020

Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/862639

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

22649447

1 reference